The cohort study used data from the TriNetX database, encompassing patients diagnosed with diabetes and prescribed ...

The FDA's new rule restricting the sale of compounded semaglutide could make it more difficult for some people to obtain ...

Biopharma leaders react to the forced resignation of CDER Head Peter Marks as RFK Jr.’s promised job cuts begin at the FDA; ...

An expected delay in a key step in CK Hutchison's planned sale of its Panama ports to a U.S. group, a deal blasted by Chinese ...

Contrave and Wegovy are both weight loss medications. Learn about their effectiveness, side effects, costs, and which ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

In brief ... 💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular ...

After revolutionizing the weight-loss drug market, Novo Nordisk (NVO) and Eli Lilly (LLY) are setting their sights on heart ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower ...